Business
Tel Aviv Sourasky Medical Center Chooses SOPHiA DDMTM HRD Solution of SOPHiA GENETICS
SOPHiA DDMTM HRD Solution will help empower clinical researchers to advance cancer research BOSTON & LAUSANNE, Switzerland--(BUSINESS WIRE)-- SOPHiA GENETICS
About this update from Sophia Genetics Sa
[{"type":"text","content":"\nSOPHiA DDMTM HRD Solution will help empower clinical researchers to advance cancer research\n\n\n BOSTON & LAUSANNE, Switzerland--(BUSINESS WIRE)--\nSOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced that Tel Aviv Sourasky Medical Center (Ichilov), the largest acute care facility in Israel, has chosen to use SOPHiA DDM™ to enhance its genetic testing capabilities. The facility, which serves a population of one million people, will use the SOPHiA DDM™ Homologous Recombination Deficiency (HRD) Solution to help advance its clinical oncology research.\n\n\nHRD is caused by a cell’s impaired ability to repair DNA double-stranded breaks through the homologous recombination repair (HRR) pathway and is a common feature of high-grade serous ovarian cancer (HGSOC) as well as breast, prostate, and pancreatic cancers. For those diagnosed with these cancer types, HRD can be used as a potential predictive biomarker for therapy response.\n\n\nThe SOPHiA DDMTM HRD Solution provides a unique approach to molecular cancer testing by combining the identification of HRD-causing mutations with the analysis of HRD-induced genomic instability across the whole genome of tumor samples. By implementing SOPHiA DDMTM HRD Solution, Tel Aviv Sourasky Medical Center (Ichilov) will have the opportunity to identify larger populations of individuals with HRD-positive cancer who may benefit from treatment with PARP inhibitors (PARPi).\n\n\n“The implementation of methods able to detect HRD is crucial for identifying patients who could benefit from treatment with PARPi,” said Dr. Ariel Erental, Tel Aviv Sourasky Medical Center. “The SOPHiA DDMTM HRD Solution will help to inform data-driven decisions that advance the clinical research at Tel Aviv Sourasky Medical Center into HRD-associated cancers.”\n\n\nSOPHiA DDMTM HRD Solution enables laboratories and healthcare institutions to identify HRR mutations and measure genomic instability via a decentralized approach. This approach to HRD testing for tumor samples allows the users to retain full ownership of their data, saving time and expense, while offering comprehensive genomic insights powered by deep learning algorithms.\n\n\n“SOPHiA GENETICS is working to make data-driven medicine more broadly accessible to patients around ...